Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012, with the announcement issued on May 23, 2012. The filing addresses a material development in GSK's ongoing tender offer to acquire Human Genome Sciences (HGS).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for GSK. The document focuses exclusively on the terms of a corporate acquisition.
- Tender Offer Price: US$13.00 per share in cash for all outstanding shares of HGS.
- Offer Expiration: Scheduled for 12:00 midnight New York City time on June 7, 2012.
Material Changes
GSK has amended the conditions of its tender offer for HGS in response to the HGS Board of Directors adopting a shareholder rights plan (commonly known as a "poison pill").
- New Condition: The offer now requires HGS to redeem the poison pill.
- Alternative Condition: Alternatively, GSK must be satisfied in its reasonable judgment that the pill has been invalidated or is otherwise inapplicable to the acquisition.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential business combination, including future financial and operating results. GSK cautions that actual results may differ materially due to risks and uncertainties.
- Advisors: Lazard and Morgan Stanley are acting as financial advisors; Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice.
- Risk Reference: Factors affecting operations are detailed in the "Risk factors" section of GSK's 2011 Annual Report (Exhibit 15.2 to Form 20-F).
- Contingency: The success of the acquisition is contingent upon the resolution of the poison pill defense.
Investor Verification Checklist
- Verify the current status of the HGS shareholder rights plan ("poison pill") and whether it has been redeemed or invalidated.
- Confirm the final expiration date and time of the tender offer (June 7, 2012).
- Review the full offer to purchase and related materials filed with the SEC for detailed terms.
- Assess the impact of the acquisition on GSK's future financial statements, noting that specific integration costs or benefits are not detailed in this filing.